Sustainability in Healthcare: Synthace’s CEO Tim Fell meets Al Gore
On Tuesday 25th June, Generation Investment Management launched their 2019 sustainability report. Our CEO Tim Fell was invited to learn first-hand about their findings and to meet with their Chairman, Al Gore.
Founded in 2004, Generation Investment Management is an investment organisation whose vision is to see long-term, sustainable investing become best practice, and for sustainable capitalism to become the enduring economic model. Their portfolio of $22.1 bn worth of assets under management mirrors their success in achieving their vision so far.
In their work, they undertake excellent and thorough research and publish their findings annually. The latest instalment of their comprehensive report looks at global sustainability issues across six areas in 2019: Finance and Economics; Health; Consumption; Energy; Industry; and Mobility.
Our CEO, Tim Fell was in attendance at the launch event for the report, hosted at the Conduit Club, London, a private members club that aims to bring together a diverse community of people passionate about enacting social change - a fitting venue for the event.
As Tim reports:
“It was a great event attended by about 100 people. However, the findings presented from the health report provided stark viewing. The data revealed a growing trend for inequality in global health.”
“It was also fantastic to meet with Al Gore and to hear first-hand from him about the mission of Generation Investment Management and the work of the Generation Foundation, and also about the need for sustainability in the health sector.”
Sustainability in health means enabling equal access to healthcare for everyone
It is also clear from the report how advances in genomic research, such as gene editing technologies, have led to a reduction in costs to work with genomic DNA. Which has directly caused the explosion of the synthetic biology, large molecule biosynthesis and cell and gene therapy sectors. And this has in turn led to a rapid rise in innovation in therapeutics.
However, there is still a question mark over the efficiency of the research and development done in these sectors, with the current cost to bring a product from discovery to launch averaging ~$1.75 bn.
As Al Gore mentioned in his address to the attendees, to make the health of our global population more sustainable the barriers to healthcare access and treatment need to be removed. The sheer costs involved in bringing a therapy to market, makes the current system unsustainable.
“…It’s about enabling scientists to do experiments that they have never been able to before, leading to better biological insights, and in turn, more sustainable products and process.”
Tim Fell, CEO Synthace Ltd.
Synthace is a disruptor in the health space
Al and Tim met in 2016 at the World Economic Forum when we were still a small start-up company. Al was highly impressed by our vision to transform biological R&D and manufacturing. Recognising the sustainability impact Synthace could have across many different sectors he wished us luck and looked forward to following our progress.
Fast-forward to 2019, and Tim was able to update Al on how Synthace is progressing in delivering that transformation.
As Tim explains:
“Al was delighted to hear how much our platform, Antha, had advanced, and how it is disrupting how biological research is done in our pharma and biotech customers.”
Synthace is a leader in Computer Aided Biology, a new way of working reliant upon automation and AI. Biology is inherently complex and its behaviour highly dependent on environmental conditions. The Company’s software allows researchers to perform holistic, multifactor experiments to navigate that complexity in ways that have never been possible before.
Biological research and, by extension, its impact on global health, is ripe for disruption.
As Tim explains:
“For research to really accelerate, scientists need a step change in the power of their tools. Antha is a game changing technology, akin to the Computer Aided Design software that transformed the automotive, aerospace and similar industries.”
“It’s not just about lowering research costs -which we do. Or, speeding everything up -which we do. It’s not just about making science more reproducible, reliable and robust -which we do. It’s about enabling scientists to do experiments that they have never been able to before, leading to better biological insights, and in turn, more sustainable products and process.”